Real-time enrollment status for this cerebral amyloid angiopathy clinical trial
Current Status
Recruiting
Checked: March 2, 2026 at 12:06 PM UTC
| NCT Number | NCT06393712 |
| Recruiting Status | Recruiting |
| Condition | Cerebral Amyloid Angiopathy |
| Phase | Clinical Trial |
| Target Enrollment | 200 participants |
| Active Locations | 26 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | February 20, 2026 (1 week ago) |
As of March 2, 2026: Clinical trial NCT06393712 is currently recruiting participants. This clinical trial study for cerebral amyloid angiopathy is actively seeking new participants at 26 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06393712 is actively recruiting participants as of March 2, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 26 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06393712 was last updated 1 week ago (February 20, 2026). HelloStudys verifies this status automatically.